Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Pathogenic bacteria in the gut are microorganisms capable of causing disease by disrupting normal intestinal function, evading host defenses, or producing toxins. These bacteria interact dynamically with the resident gut microbiota and the host immune system, influencing health and disease states. They can colonize the intestine when normal microbiota balance is disturbed, leading to overgrowth of harmful species. Pathogens employ various strategies for survival, including competing for nutrients, exploiting metabolic byproducts, producing toxins, and modulating host immune responses. Disruption of the healthy gut microbiome can reduce microbial diversity and open ecological niches for pathogens to proliferate, potentially leading to acute infections, chronic inflammation, or systemic dissemination.
Antibiotics directly target and kill/inhibit bacterial growth. Probiotics aim to restore a healthy gut microbiota. FMT replaces the patient's gut microbiota with that of a healthy donor.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Pathogenic Bacteria (Gut).